Joshua Goodin

University of Mississippi Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Robert E. Lewis

University of Nebraska Medical Center

Julius M. Cruse

University of Mississippi Medical Center

Steven A. Bigler

Jackson Memorial Hospital

Venkat K.R. Mannam

University of Mississippi Medical Center

Taryn N. Green

University of Auckland

Holly McIntire

University of Mississippi

Jeanann L. Suggs

University of Mississippi Medical Center

Morgan L. Cowan

Johns Hopkins Medicine

Bret C. Allen

University of Mississippi

Charles K. Moore

University of Mississippi Medical Center

Cooperative Institutions

University of Mississippi Medical Center

Jackson Memorial Hospital

State Street (United States)

University of Mississippi

University of Nebraska Medical Center

Victoria University of Wellington

Guy's and St Thomas' NHS Foundation Trust

University of Sheffield

ARUP Laboratories (United States)

University of Utah

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

HLA‐A*7401 and HLA‐C*0401 ALLELIC DISEASE ASSOCIATION WITH PLASMA CELL NEOPLASIA

The FASEB Journal (2012)

Venkat K.R. Mannam W. Gilbert Taryn N. Green Mark F. Santos Joshua Goodin

The present investigation was designed to show the incidence of molecular Human Leukocytic Antigen (HLA) class I and class II allelic specificities in plasma cell neoplasia patients, identified by immunohistochemistry, flow cytometry, and high resolution molecular typing. Plasma cell myeloma is the second most common hematological malignancy (13%), comprising 1% of all cancers. Each year, 21000 new cases are diagnosed with a two‐fold prevalence in African Americans in contrast to Caucasians. Our hypothesis is that plasma cell neoplasia have a significant disease association with selected HLA class I and class II alleles. We found that in African American patients diagnosed with plasma cell myeloma (n=10), 50 % expressed HLA‐A*7401 (p= 0.002) and 60% were HLA‐C*0401 positive ( p= 0.004). In patients suspected to have plasma cell neoplasia ( controls n=50), 6% were HLA‐A*7401 positive and 14% expressed HLA‐C*0401. Our results suggest that persons expressing these alleles are more likely to develop plasma cell neoplasia than are those not expressing these alleles. African American patients diagnosed with plasma cell myeloma have significant associations with HLA‐A*7401 and HLA‐C*0401 alleles. Future studies will be directed to identification of HLA class II alleles associated with plasma cell neoplasia.

10.1096/fasebj.26.1_supplement.657.18

Cite

Citations (0)

C4d staining in humoral rejection of cardiac allografts

The FASEB Journal (2008)

Julius M. Cruse Jeanann L. Suggs Robert E. Lewis Joshua Goodin Bret C. Allen

C4d “staining” of interstitial capillaries of endomyocardial biopsies serves as an indicator of a humoral component of cardiac allograft rejection. In the present study, two cardiac allograft recipients were monitored serially for both cellular and humoral rejection. Cellular rejection, evaluated by light microscopy, and humoral rejection, judged by C4d immunofluorescent “staining”, were treated with appropriate immunosuppressants. Weekly serial biopsies of the first patient for nine weeks revealed grade 1A to 1B moderate cellular rejection. Humoral rejection peaked at 3+ “staining” for C4d after one week transplant, and then wavered between 2+ (moderate “staining”) to 1+ (weak”staining”) Biopsies of the second patient revealed maximal humoral rejection (3+) after one week but diminished to 2+ thereafter. Cellular rejection was graded as 3A after three weeks but declined steadily to negligible cellular rejection through week 15. Whereas, cellular rejection peaked at 14 – 21 days, humoral rejection was greatest in the early post transplant period. Results revealed the significance not only of traditional light microscopy in evaluating the severity of cellular rejection in endomyocardial biopsies of cardiac allotransplants, but also the value of C4d immunofluorescent “staining” of interstitial capillaries as an indicator of humoral rejection episodes, which may require modified therapy.

Endomyocardial Biopsy

Humoral immunity

Positive staining

Transplant rejection

10.1096/fasebj.22.2_supplement.593

Cite

Citations (1)

CORRELATION OF DRβ1*1501, DQβ1*0602 DONOR ALLELIC HAPLOTYPE WITH HUMORAL ANTIBODY EPISODES OF ACUTE RENAL ALLOGRAFT REJECTION

The FASEB Journal (2010)

Venkat K.R. Mannam Taryn N. Green Morgan L. Cowan Joshua Goodin Robert E. Lewis

The present investigation was designed to show the effect of molecular HLA class II DR and DQ allelic differences between donor and recipient on humoral antibody rejection identified by C4d peritubular capillary staining. The hypothesis is that expression of the DRβ1*1501, DQβ1*0602 allele in the donor kidney increases the likelihood of humoral antibody rejection. We found that 67 %(n=18) of DR15 and/or DQ6 haplotype donor kidneys induce humoral antibody renal allograft rejection; 35% (n=40) of DR15 and/orDQ6 haplotype donor kidneys failed to induce humoral antibody renal allograft rejection. 41% of C4d+ recipients had donors with DR15; 15% of C4d− recipients had donors with HLA‐DR15. We compared donor haplotype alleles of 4 C4d+ with 6 C4d− recipients by high resolution molecular typing; 3 of 4 C4d+ recipients had a donor with the DRβ1*1501/DQβ1*0602 allele. This allele was absent in all C4d− donors. 35% of C4d+ recipients had 2 DR mismatches when compared to 33% of C4d− recipients. Our results, suggest that the DRβ1*1501, DQβ1*0602 allele in the donor kidney increases the risk of humoral antibody episodes of acute rejection, and signals the need for C4d staining. Future analysis of additional donor and recipient haplotypes will establish whether or not this is a useful predictor of humoral rejection episodes.

10.1096/fasebj.24.1_supplement.753.11

Cite

Citations (0)

DRβ1*1501, DQβ1*0602 donor allelic haplotype and humoral antibody episodes of acute renal allograft rejection

Experimental and Molecular Pathology (2010)

Morgan L. Cowan Venkat K.R. Mannam Taryn N. Green Joshua Goodin Robert E. Lewis

10.1016/j.yexmp.2010.06.008

Cite

Citations (3)

Serial monitoring of humoral antibody-mediated rejection of cardiac allografts by C4d staining of interstitial capillaries

Experimental and Molecular Pathology (2008)

Jeanann L. Suggs Joshua Goodin Julius M. Cruse Robert E. Lewis Bret C. Allen

Humoral immunity

Endomyocardial Biopsy

10.1016/j.yexmp.2008.11.008

Cite

Citations (4)